<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113206</article-id><article-id pub-id-type="publisher-id">ACM-41398</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_97695029.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  安立生坦治疗肺高压的疗效及临床安全性：来自5项随机双盲安慰剂对照临床试验的493名患者的荟萃分析
  The Efficiency and Clinical Adverse Effects of Ambrisentan for Pulmonary Hypertension: Insights from the Meta-Analysis of 493 Patients from 5 Randomized Double-Blind Placebo-Controlled Clinical Trials
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>谢</surname><given-names>奉初</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>粒蜜</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>易</surname><given-names>岂建</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>重庆医科大学附属儿童医院心血管内科，儿童发育疾病研究教育部重点实验室，国家儿童健康与疾病临床医学研究中心，儿童发育重大疾病国际科技合作基地，儿科学重庆市重点实验室，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1437</fpage><lpage>1448</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：安立生坦是一种高选择性的内皮素受体拮抗剂，已广泛应用于肺高压(pulmonary hypertension, PH)，但临床不良反应和疗效报道有限，主要来源于个体试验，因此，我们进行了荟萃分析，观察安立生坦的疗效及安全性。方法：系统检索PubMed、Embase、Cochrane数据库和clintrials.gov网站后，纳入至少1个试验组接受安立生坦治疗的随机对照试验(randomized controlled trials, RCTs)。评价安立生坦的临床不良事件(adverse events, AEs)和疗效。根据研究间的异质性，使用随机或固定效应模型。结果：共纳入5项临床随机对照研究493例患者。在平均24周的随访中，安立生坦组6分钟步行距离(6-min walk distance, 6MWD)增加了37.53米，减少临床恶化、血浆B型利钠肽(B-type natriuretic peptide, BNP)浓度降低。安立生坦组外周水肿(18.94% vs 7.91%; RR = 1.58, 95% CI 1.01~2.45, P = 0.04)和鼻塞(7.34% vs 2.04%; RR = 3.25, 95% CI 1.08~9.79, P = 0.04)的发生率显著高于安慰剂组。安立生坦组没有发现其他副反应发生率显著升高。结论：安立生坦能显著提高PH患者的运动耐力，减少临床恶化，而不良反应无明显增加。
    Objective: Ambrisentan, a highly selective endothelin receptor antagonist (ERA), has been widely applied in patients with pulmonary hypertension (PH). It is necessary to evaluate the clinical effects and adverse reaction of ambrisentan in PH. Methods: After systematic searches of PubMed, Embase, Cochrane Library and the Clinical Trials.gov website, randomized controlled trials (RCTs) with patients receiving ambrisentan in at least 1 treatment group were included. The clinical adverse events (AEs) and the efficiency of ambrisentan were evaluated. Summary relative risks and 95% CIs were calculated using random- or fixed-effects models according to between-study heterogeneity. Results: In total, 5 randomized trials including 493 patients met the inclusion criteria. At an average follow-up of 24 weeks, the ambrisentan group had increased 37.53 m in 6-min walk distance (6MWD), decreased clinical worsening, and decreased plasma B-type natriuretic peptide (BNP) concentration. Meta-analysis showed that the incidence of peripheral edema (18.94% versus 7.91%; RR 1.58, 95% CI 1.01~2.45, P = 0.04), and nasal congestion (7.34% versus 2.04%; RR 3.25, 95% CI 1.08~9.79, P = 0.04) was significantly higher in the ambrisentan group compared with placebo. Ambrisentan was not found to increase other reported AEs compared with placebo. Conclusions: Ambrisentan in PH is well established and still requires clinical trials for an identification of its efficiency on PH patients for an optimized period lessening a serious complication and the common AEs. 
  
 
</p></abstract><kwd-group><kwd>肺高压，安立生坦，荟萃分析, Pulmonary Hypertension</kwd><kwd> Ambrisentan</kwd><kwd> Meta-Analysis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：安立生坦是一种高选择性的内皮素受体拮抗剂，已广泛应用于肺高压(pulmonary hypertension, PH)，但临床不良反应和疗效报道有限，主要来源于个体试验，因此，我们进行了荟萃分析，观察安立生坦的疗效及安全性。方法：系统检索PubMed、Embase、Cochrane数据库和clintrials.gov网站后，纳入至少1个试验组接受安立生坦治疗的随机对照试验(randomized controlled trials, RCTs)。评价安立生坦的临床不良事件(adverse events, AEs)和疗效。根据研究间的异质性，使用随机或固定效应模型。结果：共纳入5项临床随机对照研究493例患者。在平均24周的随访中，安立生坦组6分钟步行距离(6-min walk distance, 6MWD)增加了37.53米，减少临床恶化、血浆B型利钠肽(B-type natriuretic peptide, BNP)浓度降低。安立生坦组外周水肿(18.94% vs 7.91%; RR = 1.58, 95% CI 1.01~2.45, P = 0.04)和鼻塞(7.34% vs 2.04%; RR = 3.25, 95% CI 1.08~9.79, P = 0.04)的发生率显著高于安慰剂组。安立生坦组没有发现其他副反应发生率显著升高。结论：安立生坦能显著提高PH患者的运动耐力，减少临床恶化，而不良反应无明显增加。</p></sec><sec id="s2"><title>关键词</title><p>肺高压，安立生坦，荟萃分析</p></sec><sec id="s3"><title>The Efficiency and Clinical Adverse Effects of Ambrisentan for Pulmonary Hypertension: Insights from the Meta-Analysis of 493 Patients from 5 Randomized Double-Blind Placebo-Controlled Clinical Trials<sup> </sup></title><p>Fengchu Xie, Limi Xu, Qijian Yi</p><p>Department of Cardiology, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Developmental Disorder, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing</p><p><img src="//html.hanspub.org/file/89-1572065x4_hanspub.png" /></p><p>Received: Feb. 25<sup>th</sup>, 2021; accepted: Mar. 12<sup>th</sup>, 2021; published: Mar. 31<sup>st</sup>, 2021</p><p><img src="//html.hanspub.org/file/89-1572065x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: Ambrisentan, a highly selective endothelin receptor antagonist (ERA), has been widely applied in patients with pulmonary hypertension (PH). It is necessary to evaluate the clinical effects and adverse reaction of ambrisentan in PH. Methods: After systematic searches of PubMed, Embase, Cochrane Library and the Clinical Trials.gov website, randomized controlled trials (RCTs) with patients receiving ambrisentan in at least 1 treatment group were included. The clinical adverse events (AEs) and the efficiency of ambrisentan were evaluated. Summary relative risks and 95% CIs were calculated using random- or fixed-effects models according to between-study heterogeneity. Results: In total, 5 randomized trials including 493 patients met the inclusion criteria. At an average follow-up of 24 weeks, the ambrisentan group had increased 37.53 m in 6-min walk distance (6MWD), decreased clinical worsening, and decreased plasma B-type natriuretic peptide (BNP) concentration. Meta-analysis showed that the incidence of peripheral edema (18.94% versus 7.91%; RR 1.58, 95% CI 1.01~2.45, P = 0.04), and nasal congestion (7.34% versus 2.04%; RR 3.25, 95% CI 1.08~9.79, P = 0.04) was significantly higher in the ambrisentan group compared with placebo. Ambrisentan was not found to increase other reported AEs compared with placebo. Conclusions: Ambrisentan in PH is well established and still requires clinical trials for an identification of its efficiency on PH patients for an optimized period lessening a serious complication and the common AEs.</p><p>Keywords:Pulmonary Hypertension, Ambrisentan, Meta-Analysis</p><disp-formula id="hanspub.41398-formula136"><graphic xlink:href="//html.hanspub.org/file/89-1572065x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/89-1572065x7_hanspub.png" /> <img src="//html.hanspub.org/file/89-1572065x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>肺动脉高压(pulmonary hypertension, PH)的特征是肺血管重构导致肺动脉压(pulmonary arterial pressure, PAP)升高，随着时间的推移，右心室功能障碍，左心室充盈不足或受压，最终导致过早死亡早死 [<xref ref-type="bibr" rid="hanspub.41398-ref1">1</xref>]。近年来，由于对发病机制的研究和靶向药物的开发，PH患者的预后得到了显著改善。</p><p>安立生坦是一种高选择性的内皮素A受体(endothelin A, ET<sub>A</sub>)拮抗剂。可拮抗ET<sub>A</sub>的血管收缩作用，同时保留内皮素B受体(endothelin B, ET<sub>B</sub>)清除内皮素(endothelin-1, ET-1)的作用 [<xref ref-type="bibr" rid="hanspub.41398-ref2">2</xref>]。迄今为止，一些已发表的随机双盲安慰剂对照临床试验表明，安立生坦可显著改善PH患者的运动能力、症状、心肺血流动力学，并减缓临床恶化。随着安立生坦的临床应用逐渐广泛，其不良反应如周围水肿、鼻塞、头痛等逐渐被报道。因此，有必要评估安立生坦在临床患者中的安全性和有效性。</p><p>大多数安立生坦临床研究包括的样本量有限。为了提高准确性，结合个别研究的结果并得出单一的主要效应，我们对安立生坦的不良反应和有效性进行了系统回顾和荟萃分析。</p></sec><sec id="s6"><title>2. 研究方法</title><sec id="s6_1"><title>2.1. 数据来源及搜索</title><p>检索数据库包括PubMed，Embase，Cochrane Library，和ClinicalTrials.gov (至2020年6月)。检索关键词为“ambrisentan and pulmonary hypertension”，并以“human、English、randomized-controlled trial”为限制条件。为了尽量避免遗漏文献，在阅读文献时，详细检查其参考文献。</p></sec><sec id="s6_2"><title>2.2. 文献纳排标准</title><p>纳入标准：1) RCT研究；2) 研究对象为人类；3) 研究对象患有任何一种疾病；4) 研究对象中至少有一组接受安立生坦治疗；5) 研究中分别报道了安立生坦组及对照组的疗效及不良反应。对于有多个研究组的文献，我们纳入与纳入标准相符的研究组。</p><p>排除标准：1) 不能提取准确数据；2) 个案报道、综述、文献实验室研究或动物实验；3) 会议摘要或会议报告。</p></sec><sec id="s6_3"><title>2.3. 数据提取及文献质量评价</title><p>两名研究者独立进行文献检索，并获取所有可能符合纳入标准文章的全文进行仔细阅读，如遇意见不统一，进行讨论，如仍有分歧，与第三位研究者讨论协商。从每项研究中提取的数据包括第一作者姓名、发表年份、研究设计、研究持续时间、研究人群特征(年龄、性别和患者数量)、干预措施(活性药物)、结果(主要结果和次要结果)、随访时间和所有报告的不良事件。</p><p>我们使用Gummesson [<xref ref-type="bibr" rid="hanspub.41398-ref3">3</xref>] 改良Jadad [<xref ref-type="bibr" rid="hanspub.41398-ref4">4</xref>] 评分来评估研究的质量。改良Jadad评分总分为5分，小于等于3分为低质量，大于等于4分为高质量。</p></sec><sec id="s6_4"><title>2.4. 偏倚评估</title><p>我们使用Cochrane系统评价手册5.1.0中描述的标准来评估纳入研究中的试验水平偏倚风险 [<xref ref-type="bibr" rid="hanspub.41398-ref5">5</xref>]。两名评审员独立评估研究的偏倚风险。通过讨论和协商一致解决了所有分歧，同时绘制漏斗图以评估出版偏倚。</p></sec><sec id="s6_5"><title>2.5. 统计学方法</title><p>本文使用Review Manager 5.4进行Meta分析。个体研究和荟萃分析估计值用森林图呈现，对于非连续性变量计算其比值比，对于连续变量则计算其标准化均数差值和95%置信区间(confidence intervals, CIs)。异质性通过I<sup>2</sup>检验进行评估，该检验衡量了研究之间总变异的百分比。对于每个荟萃分析，进行了效应分析；若研究间异质性低(I<sup>2</sup> &lt; 50%)，则使用固定效应模式；若研究间异质性检验有意义或高度不一致时(I<sup>2</sup> ≥ 50%)选用随机效应模式 [<xref ref-type="bibr" rid="hanspub.41398-ref6">6</xref>]，并通过敏感性分析探讨异质性来源。如果研究没有报道数据的平均值和标准差，我们通过Greenland [<xref ref-type="bibr" rid="hanspub.41398-ref7">7</xref>] 建议的方法从图表中计算得出。P &lt; 0.05表明存在统计学显著差异。</p></sec></sec><sec id="s7"><title>3. 研究结果</title><sec id="s7_1"><title>3.1. 文献检索结果</title><p>通过检索数据库：PubMed，Embase，Cochrane library，ClinicalTrials.gov，共得到相关文献252篇，严格按照纳入排除标准进行筛查共得4篇文献共包含5个随机对照实验(文献筛选流程见图1)。最终，共493名患者被纳入研究，其中治疗组，318人，对照组175人。表1显示了纳入研究的基本特征。偏倚风险在图2中显示。</p><p>图1. 文献筛选流程图.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The baseline characteristics and Jadad score of six studies included in meta-analysi</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Source</th><th align="center" valign="middle"  rowspan="2"  >Design</th><th align="center" valign="middle"  rowspan="2"  >Duration (weeks)</th><th align="center" valign="middle"  rowspan="2"  >Disease</th><th align="center" valign="middle"  colspan="2"  >Trial group</th><th align="center" valign="middle"  colspan="2"  >Control group</th><th align="center" valign="middle"  rowspan="2"  >Jadad scale</th></tr></thead><tr><td align="center" valign="middle" >Treatment</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >Treatment</td><td align="center" valign="middle" >n</td></tr><tr><td align="center" valign="middle" >Gali&#232; N et al., 2008 ARIES 1 [<xref ref-type="bibr" rid="hanspub.41398-ref20">20</xref>]</td><td align="center" valign="middle" >RCT</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >PAH</td><td align="center" valign="middle" >Ambrisentan 5/10 mg QD</td><td align="center" valign="middle" >67/67</td><td align="center" valign="middle" >placebo</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >Gali&#232; N et al., 2008 ARIES 2 [<xref ref-type="bibr" rid="hanspub.41398-ref20">20</xref>]</td><td align="center" valign="middle" >RCT</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >PAH</td><td align="center" valign="middle" >Ambrisentan 2.5/5 mg QD</td><td align="center" valign="middle" >64/63</td><td align="center" valign="middle" >placebo</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >Pilar E-S et al., 2018 [<xref ref-type="bibr" rid="hanspub.41398-ref21">21</xref>]</td><td align="center" valign="middle" >RCT</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >CTEPH</td><td align="center" valign="middle" >Ambrisentan 5 mg QD</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >placebo</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >ARTEMIS-PH [<xref ref-type="bibr" rid="hanspub.41398-ref23">23</xref>]</td><td align="center" valign="middle" >RCT</td><td align="center" valign="middle" >56</td><td align="center" valign="middle" >IPF</td><td align="center" valign="middle" >Ambrisentan 10 mg QD</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >placebo</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >Zixuan P et al., 2019 [<xref ref-type="bibr" rid="hanspub.41398-ref22">22</xref>]</td><td align="center" valign="middle" >RCT</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >SSC</td><td align="center" valign="middle" >Ambrisentan 10 mg QD</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >placebo</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >5</td></tr></tbody></table></table-wrap><p>表1. 全部纳入研究的基本特点</p><p>PAH = 肺动脉高；CTEPH = 慢性血栓栓塞性肺动脉高压；IPAH = 特发性肺动脉高压；SSc = 系统性硬化病。</p><p>图2. 所有文献的偏倚评估，+ 低风险；-高风险；? 风险未知</p></sec><sec id="s7_2"><title>3.2. 文献质量评价</title><p>采用了Gummesson [<xref ref-type="bibr" rid="hanspub.41398-ref3">3</xref>] 改良的Jadad [<xref ref-type="bibr" rid="hanspub.41398-ref4">4</xref>] 评分对研究进行质量评估。根据4项评定标准：随机试验、隐藏分配、双盲、失访率。5项研究Jadad评分均大于等于4分，均符合高质量标准(表2)。</p></sec><sec id="s7_3"><title>3.3. 疗效分析</title><sec id="s7_3_1"><title>3.3.1. 6MWD</title><p>5项研究均6MWD作为主要终点事件，各研究之间无统计学异质性(P = 0.74, I<sup>2</sup> = 0%)。与安慰剂相比，安立生坦组6MWD增加了37.53 m (95% CI = 20.88~54.18, P &lt; 0.00001)。根据安立生坦的治疗剂量进行亚组分析，6MWD分别在5 mg组增加了38.03 m (95% CI = 16.57~59.50, P = 0.0005)、10 mg组增加了43.68 m (95% CI = 19.31~68.05, P = 0.0004)，但2.5 mg组与安慰剂组之间无统计学差异(图3)。</p><p>图3. 安立生坦组6分钟步行距离与对照组比较</p></sec><sec id="s7_3_2"><title>3.3.2. 临床恶化率</title><p>临床恶化定义为患者死亡、临床症状加重、因肺动脉高压失代偿而住院、肺移植 [<xref ref-type="bibr" rid="hanspub.41398-ref8">8</xref>]。3项研究中出现临床恶化，且各研究间无异质性(P = 0.19, I<sup>2</sup> = 39%)。安立生坦组的临床恶化发生率低于安慰剂组(RR = 0.39, 95% CI = 0.24~0.66, P = 0.0004) (图4)。</p><p>图4. 安立生坦组临床恶化率与对照组相比</p></sec><sec id="s7_3_3"><title>3.3.3. 血浆BNP浓度</title><p>在ARISE1及ARISE2研究中，血浆BNP浓度的基线水平相似。经过12周的治疗后，安慰剂组的血浆BNP浓度较基线增加9% (ARIES-1)和13% (ARIES-2)。相比之下，ARISE1的5 mg组(30%)和10 mg组(45%)以及ARISE2的2.5 mg组(29%)和5 mg组(30%)血浆BNP浓度均较基线下降(所有P &lt; 0.003)。在Pilar的研究中，BNP浓度从基线值变化−29.4% (5 mg安立生坦组)和14.1% (安慰剂组)。而在Zixuan的研究中，安慰剂组BNP浓度从基线值变化为31.00 &#177; 85.83 (95% CI = −20.87~82.87)，安立生坦组变化为−15.63 &#177; 207.48 (95% CI = −126.18~94.93)，但他们之间无统计学差异。</p></sec></sec><sec id="s7_4"><title>3.4. 安全性</title><p>总体来说，安立生坦具有良好的耐受性，5项研究中的共报道AEs 491件，多为轻到中度。常见AEs包括外周水肿、鼻塞、头痛等，我们选取至少在2研究中出现的事件，并将安立生坦组及治疗组的绝对和相对频率进行分析。以下项目纳入研究：心血管疾病(心悸)、胃肠道疾病(腹部不适、腹泻、便秘)、一般性疾病(外周水肿、鼻塞、脸红、鼻衄)、感染(鼻窦炎、上呼吸道感染)、神经系统疾病(头痛)、呼吸系统疾病(呼吸困难)。表2中列出了相对应的95% CIs及P值。其中，安立生坦组与安慰剂组相比，外周水肿和鼻塞的发生频率具有统计学意义。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Relative risk of known adverse events reported for ambrisentan in comparison with placeb</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >ADR outcome</th><th align="center" valign="middle" >Studies</th><th align="center" valign="middle" >Participants</th><th align="center" valign="middle" >RR (95% CI)</th><th align="center" valign="middle" >Incidence rate (%)</th><th align="center" valign="middle" >P Value</th><th align="center" valign="middle" >Effect Model</th></tr></thead><tr><td align="center" valign="middle"  colspan="6"  >Cardiovascular disorders</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >palpitations</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >433</td><td align="center" valign="middle" >1.45 (0.49~4.25)</td><td align="center" valign="middle" >4.2</td><td align="center" valign="middle" >0.5</td><td align="center" valign="middle" >Fixed</td></tr><tr><td align="center" valign="middle"  colspan="6"  >Gastrointestinal disorders</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >abdominal discomfort</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >433</td><td align="center" valign="middle" >1.59 (0.51~4.97)</td><td align="center" valign="middle" >4.2</td><td align="center" valign="middle" >0.43</td><td align="center" valign="middle" >Fixed</td></tr><tr><td align="center" valign="middle" >diarrhea</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >0.39 (0.1~1.54)</td><td align="center" valign="middle" >4.55</td><td align="center" valign="middle" >0.18</td><td align="center" valign="middle" >Fixed</td></tr><tr><td align="center" valign="middle" >constipation</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >466</td><td align="center" valign="middle" >2.16 (0.72~6.51)</td><td align="center" valign="middle" >4.95</td><td align="center" valign="middle" >0.44</td><td align="center" valign="middle" >Fixed</td></tr><tr><td align="center" valign="middle"  colspan="6"  >General disorders</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >peripheral edema</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >504</td><td align="center" valign="middle" >1.58 (1.01~2.45)</td><td align="center" valign="middle" >18.94</td><td align="center" valign="middle" >0.04</td><td align="center" valign="middle" >Fixed</td></tr><tr><td align="center" valign="middle" >nasal congestion</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >433</td><td align="center" valign="middle" >3.25 (1.08~9.79)</td><td align="center" valign="middle" >7.34</td><td align="center" valign="middle" >0.006</td><td align="center" valign="middle" >Fixed</td></tr><tr><td align="center" valign="middle" >flushing</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >433</td><td align="center" valign="middle" >1.75 (0.53~5.79)</td><td align="center" valign="middle" >3.85</td><td align="center" valign="middle" >0.36</td><td align="center" valign="middle" >Fixed</td></tr><tr><td align="center" valign="middle" >epistaxis</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >1.96 (0.38~9.96)</td><td align="center" valign="middle" >11.11</td><td align="center" valign="middle" >0.42</td><td align="center" valign="middle" >Fixed</td></tr><tr><td align="center" valign="middle"  colspan="6"  >Infections</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >sinusitis</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >433</td><td align="center" valign="middle" >2.64 (0.57~12.15)</td><td align="center" valign="middle" >3.15</td><td align="center" valign="middle" >0.21</td><td align="center" valign="middle" >Fixed</td></tr><tr><td align="center" valign="middle" >upper respiratory tract infection</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >466</td><td align="center" valign="middle" >1.39 (0.52~3.71)</td><td align="center" valign="middle" >4.29</td><td align="center" valign="middle" >0.5</td><td align="center" valign="middle" >Fixed</td></tr><tr><td align="center" valign="middle"  colspan="6"  >Nervous system disorders</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >headache</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >504</td><td align="center" valign="middle" >1.19 (0.8~1.79)</td><td align="center" valign="middle" >18.95</td><td align="center" valign="middle" >0.39</td><td align="center" valign="middle" >Fixed</td></tr><tr><td align="center" valign="middle" >dizziness</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >111</td><td align="center" valign="middle" >0.22 (0.04~1.12)</td><td align="center" valign="middle" >1.64</td><td align="center" valign="middle" >0.07</td><td align="center" valign="middle" >Fixed</td></tr><tr><td align="center" valign="middle"  colspan="7"  >Respiratory disorders</td></tr><tr><td align="center" valign="middle" >dyspnea</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >433</td><td align="center" valign="middle" >1.16 (0.56~2.39)</td><td align="center" valign="middle" >6.64</td><td align="center" valign="middle" >0.69</td><td align="center" valign="middle" >Fixed</td></tr></tbody></table></table-wrap><p>表2. 安立生坦已知不良事件的相对风险</p><sec id="s7_4_1"><title>3.4.1. 外周水肿</title><p>数据显示，与安慰剂组相比，安立生坦组发生外周水肿的风险显著更高(18.94% vs 12.63%；RR = 1.58, 95% CI = 1.01~2.45, P = 0.04)。根据安立生坦不同的治疗剂量进行亚组分析，10 mg组(RR = 2.08, 95% CI = 1.19~3.64, P = 0.01)、5 mg组(RR = 1.69, 95% CI = 0.95~3.01, P = 0.07)、2.5 mg组(RR = 0.29, 95% CI= 0.06~1.34, P = 0.11)，结果显示，安立生坦10 mg组外周水肿发生率与安慰剂组有统计学差异(图5)。提示外周水肿的发生可能与安立生坦的剂量呈正相关。</p><p>图5. 安立生坦组水肿发生率与对照组比较</p></sec><sec id="s7_4_2"><title>3.4.2. 鼻塞</title><p>安立生坦组鼻塞发生率明显高于对照组(7.34% vs 2.04%; RR 3.25, 95% CI = 1.08~9.79, P = 0.04)。在亚组分析中，安立生坦10 mg组(RR = 3.54, 95% CI = 1.04~12.02, P = 0.04)，5 mg组(RR = 3.03, 95% CI = 0.74~12.38, P = 0.12)，和2.5 mg组(RR = 3.05, 95% CI = 0.13~73.41, P = 0.49)，其中10 mg组鼻塞发生概率与安慰剂组具有统计学意义，提示鼻塞的发生与可能安立生坦的剂量呈正相关(图6)。</p><p>图6. 安立生坦组鼻塞发生率与对照组比较</p></sec></sec><sec id="s7_5"><title>3.5. 发表偏倚</title><p>视觉检查漏斗图分析显示适度对称性，几乎没有证据表明发表偏倚(图7)。</p><p>图7. 发表偏倚</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>ET-1是血管内皮细胞产生的内源性肽，通过与G蛋白偶联受体结合发挥作用 [<xref ref-type="bibr" rid="hanspub.41398-ref9">9</xref>]。ET<sub>A</sub>主要表达于血管平滑肌细胞和心肌细胞，而ET<sub>B</sub>主要表达于内皮细胞、平滑肌细胞和成纤维细胞 [<xref ref-type="bibr" rid="hanspub.41398-ref10">10</xref>]。ET<sub>A</sub>亚型的激活和与平滑肌细胞上的ET<sub>B</sub>结合均可诱导血管收缩。同时内皮细胞上的ET<sub>B</sub>通过释放NO、前列环素和清除ET-1来促进血管舒张 [<xref ref-type="bibr" rid="hanspub.41398-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.41398-ref11">11</xref>]，此外，ET<sub>A</sub>和ET<sub>B</sub>均介导血管平滑肌细胞增殖。在健康个体中，内源性血管收缩剂/有丝分裂原和血管扩张剂/抗有丝分裂剂之间的平衡被认为介导了低基底肺血管张力和内稳态。对于PH患者，ET-1在肺部激活，导致血管收缩和肺微循环重构 [<xref ref-type="bibr" rid="hanspub.41398-ref12">12</xref>]。因此，内皮素受体拮抗剂(ERAs)已被确定为大多数PH患者的一线治疗选择。</p><p>ET<sub>A</sub>是人肺组织中主要的内皮素受体亚型，其与ET<sub>B</sub>亚型的比值为93:7 [<xref ref-type="bibr" rid="hanspub.41398-ref13">13</xref>]。因此，作为一种选择性ET<sub>A</sub>受体拮抗剂，安立生坦应该比非选择性ERA，如波生坦、马西替坦更有效。已有研究表明，安立生坦的绝对生物利用度为90%，远高于波生坦和马西替坦(50%~70%) [<xref ref-type="bibr" rid="hanspub.41398-ref14">14</xref>]，常容易被体循环吸收。这些都可能与安立生坦性能更加优越有关。</p><p>6分钟步行试验是一种常用的客观评估功能运动能力的测试，用于管理中重度肺部疾病患者。它提供的信息是病人进行日常活动的能力高低。该测试不需要复杂的设备或技术专长。在这个低复杂性、安全的测试中，病人被要求尽快沿着一条至少30米长的走廊，步行6分钟，主要结果指标是6 MWD [<xref ref-type="bibr" rid="hanspub.41398-ref15">15</xref>]。它也被用于一次性评估患者的功能状态，预测的发病率和死亡率 [<xref ref-type="bibr" rid="hanspub.41398-ref16">16</xref>]。</p><p>由于目前的指南强调运动能力恶化(定义为WHO功能分级II级或更糟)时开始治疗，能够提高运动能力的措施被大家所重视。本研究表明，安立生坦可以有效改善PH患者的6MWD和血浆BNP浓度，这两个指标是预后较好的标志。</p><p>临床恶化定义为患者死亡、临床症状加重、因肺动脉高压失代偿而住院、肺移植，在最近的随机试验中，越来越多的将其作为主要结果报道。在我们的研究中，安立生坦与减少临床恶化有关。但本研究纳入数量较少，可能不足以评估它，特别是考虑到它们的随访时间很短，导致了对治疗后期的评价不足。长期对注册患者的随访可在今后进一步分析这一重要的终点。</p><p>肝氨基转移酶升高是与ERAs相关的主要严重不良反应。虽然肝毒性的机制仍未完全阐明，但肝胆道清除胆盐障碍已成为主要推测。肝细胞对胆汁酸的摄取主要是在有机阴离子转运多肽(organic anion-transporting polypeptides, OATPs)的支持下，由基低外侧Na<sup>+</sup>-牛磺胆酸共转运多肽(Na<sup>+</sup>-taurocholate cotransporting polypeptide, NTCP)介导的。此外，胆汁盐出口泵(bile salt export pump, BSEP)和多药耐药相关蛋白2 (multidrug resistance-associated protein 2, MRP2)也参与胆汁分泌 [<xref ref-type="bibr" rid="hanspub.41398-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.41398-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.41398-ref19">19</xref>]。ERAs可引起特定蛋白功能障碍，可能由于细胞内胆盐的积累而导致胆汁淤积性肝损伤。在肝细胞健康(细胞三磷酸腺苷/谷胱甘肽含量)、功能(尿素生产/白蛋白分泌)和牛磺胆酸运输(胆汁清除/排泄指数)的影响方面，安立生坦的作用最弱，而波生坦、马西替坦对肝胆运输的影响更强 [<xref ref-type="bibr" rid="hanspub.41398-ref19">19</xref>]。因此，安立生坦的发生肝功能损害的可能性较低。在本研究中，除一般副作用如头痛、周围水肿、鼻塞、潮红和恶心外，没有氨基转移酶升高的报道。由此可见，安立生坦的安全性优于其他ERAs。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，安立生坦能够有效改善PH患者的6MWD、延缓临床恶化、改善血浆BNP浓度，而不良反应较少，能够安全有效地治疗PH。</p></sec><sec id="s10"><title>文章引用</title><p>谢奉初,徐粒蜜,易岂建. 安立生坦治疗肺高压的疗效及临床安全性：来自5项随机双盲安慰剂对照临床试验的493名患者的荟萃分析The Efficiency and Clinical Adverse Effects of Ambrisentan for Pulmonary Hypertension: Insights from the Meta-Analysis of 493 Patients from 5 Randomized Double-Blind Placebo-Controlled Clinical Trials[J]. 临床医学进展, 2021, 11(03): 1437-1448. https://doi.org/10.12677/ACM.2021.113206</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41398-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Rubin, L.J. and Galiè, N. (2004) Pulmonary Arterial Hypertension: A Look to the Future. Journal of the American College of Cardiology, 43, S89-S90. &lt;br&gt;https://doi.org/10.1016/j.jacc.2004.02.030</mixed-citation></ref><ref id="hanspub.41398-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Seo, B., Oemar, B., Siebenmann, R., et al. (1994) Both ETA and ETB Receptors Mediate Contraction to Endothelin-1 in Human Blood Vessels. Circulation, 89, 1203-1208. &lt;br&gt;https://doi.org/10.1161/01.CIR.89.3.1203</mixed-citation></ref><ref id="hanspub.41398-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Gummesson, C., Atroshi, I. and Ekdahl, C. (2004) The Quality of Reporting and Outcome Measures in Randomized Clinical Trials Related to Upper-Extremity Disorders. Journal of Hand Surgery, 29, 727-734.  
&lt;br&gt;https://doi.org/10.1016/j.jhsa.2004.04.003</mixed-citation></ref><ref id="hanspub.41398-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Jadad, A.R., Moore, R.A., Carroll, D., et al. (1996) Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary? Controlled Clinical Trials, 17, 1-12. &lt;br&gt;https://doi.org/10.1016/0197-2456(95)00134-4</mixed-citation></ref><ref id="hanspub.41398-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Higgins, J. and Green, S. (2011) Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database of Systematic Reviews, 2011, No. 14.</mixed-citation></ref><ref id="hanspub.41398-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Xu, R., Ding, S., Zhao, Y., et al. (2014) Autologous Transplantation of Bone Marrow/Blood-Derived Cells for Chronic Ischemic Heart Disease: A Systematic Review and Meta-Analysis. Canadian Journal of Cardiology, 30, 1370-1377.  
&lt;br&gt;https://doi.org/10.1016/j.cjca.2014.01.013</mixed-citation></ref><ref id="hanspub.41398-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Greenland, S. (1987) Quantitative Methods in the Review of Epidemiologic Literature 1. Epidemiologic Reviews, 9, 1-30. &lt;br&gt;https://doi.org/10.1093/oxfordjournals.epirev.a036298</mixed-citation></ref><ref id="hanspub.41398-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Jain, S., Khera, R., Girotra, S., et al. (2017) Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis. Chest, 151, 90-105.  
&lt;br&gt;https://doi.org/10.1016/j.chest.2016.08.1461</mixed-citation></ref><ref id="hanspub.41398-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Davenport, A.P. (2002) International Union of Pharmacology. XXIX. Update on Endothelin Receptor Nomenclature. Pharmacological Reviews, 54, 219-226. &lt;br&gt;https://doi.org/10.1124/pr.54.2.219</mixed-citation></ref><ref id="hanspub.41398-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Badesch, D.B. and Humbert, M. (2008) Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension. John Wiley &amp; Sons, Ltd, Hoboken.</mixed-citation></ref><ref id="hanspub.41398-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Sato, K., Oka, M., Hasunuma, K., et al. (1995) Effects of Separate and Combined ETA and ETB Blockade on ET-1-Induced Constriction in Perfused Rat Lungs. American Journal of Physiology, 269, 668-672.  
&lt;br&gt;https://doi.org/10.1152/ajplung.1995.269.5.L668</mixed-citation></ref><ref id="hanspub.41398-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Giaid, A., Yanagisawa, M., Langleben, D., et al. (1993) Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension. The New England Journal of Medicine, 328, 1732-1739.  
&lt;br&gt;https://doi.org/10.1056/NEJM199306173282402</mixed-citation></ref><ref id="hanspub.41398-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Fukuroda, T., Kobayashi, M., Ozaki, S., et al. (1994) Endothelin Receptor Subtypes in Human versus Rabbit Pulmonary Arteries. Journal of Applied Physiology, 76, 1976-1982. &lt;br&gt;https://doi.org/10.1152/jappl.1994.76.5.1976</mixed-citation></ref><ref id="hanspub.41398-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Lepist, E.-I., Gillies, H., Smith, W., et al. (2014) Evaluation of the Endothelin Receptor Antagonists Ambrisentan, Bosentan, Macitentan, and Sitaxsentan as Hepatobiliary Transporter Inhibitors and Substrates in Sandwich-Cultured Human Hepatocytes. PLoS ONE, 9, e87548. &lt;br&gt;https://doi.org/10.1371/journal.pone.0087548</mixed-citation></ref><ref id="hanspub.41398-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Agarwala, P. and Salzman, S.H. (2020) Six-Minute Walk Test: Clinical Role, Technique, Coding and Reimbursement. Chest, 157, 603-611. &lt;br&gt;https://doi.org/10.1016/j.chest.2019.10.014</mixed-citation></ref><ref id="hanspub.41398-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Fritz, J.S., Blair, C., Oudiz, R.J., et al. (2013) Baseline and Follow-Up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension. Chest, 143, 315-323.  
&lt;br&gt;https://doi.org/10.1378/chest.12-0270</mixed-citation></ref><ref id="hanspub.41398-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Mano, Y., Usui, T. and Kamimura, H. (2010) Effects of Bosentan, an Endothelin Receptor Antagonist, on Bile Salt Export Pump and Multidrug Resistance-Associated Protein 2. Biopharmaceutics &amp; Drug Disposition, 28, 13-18.  
&lt;br&gt;https://doi.org/10.1002/bdd.527</mixed-citation></ref><ref id="hanspub.41398-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Fattinger, K., Funk, C., Pantze, M., et al. (2001) The Endothelin Antagonist Bosentan Inhibits the Canalicular Bile Salt Export Pump: A Potential Mechanism for Hepatic Adverse Reactions. Clinical Pharmacology &amp; Therapeutics, 69, 223-231. &lt;br&gt;https://doi.org/10.1067/mcp.2001.114667</mixed-citation></ref><ref id="hanspub.41398-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Aleo, M.D., Ukairo, O., Moore, A., et al. (2019) Liver Safety Evaluation of Endothelin Receptor Antagonists Using HepatoPac: A Single Model Impact Assessment on Hepatocellular Health, Function and Bile Acid Disposition. Journal of Applied Toxicology, 39, 1192-1207. &lt;br&gt;https://doi.org/10.1002/jat.3805</mixed-citation></ref><ref id="hanspub.41398-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Galie, N., Olschewski, H., Oudiz, R.J., et al. (2008) Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation, 117, 3010-3019.  
&lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.107.742510</mixed-citation></ref><ref id="hanspub.41398-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Escribano-Subias, P., Bendjenana, H., Curtis, P.S., et al. (2019) Ambrisentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Pulmonary Circulation, 9, No. 2.  
&lt;br&gt;https://doi.org/10.1177/2045894019846433</mixed-citation></ref><ref id="hanspub.41398-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">ARTEMIS-PH—Study of Ambrisentan in Subjects with Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis. &lt;br&gt;https://www.clinicaltrials.gov/ct2/show/results/NCT00879229</mixed-citation></ref><ref id="hanspub.41398-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Pan, Z., Marra, A.M., Benjamin, N., et al. (2019) Early Treatment with Ambrisentan of Mildly Elevated Mean Pulmonary Arterial Pressure Associated with Systemic Sclerosis: A Randomized, Controlled, Double-Blind, Parallel Group Study (EDITA Study). Arthritis Research &amp; Therapy, 21, Article No. 217. &lt;br&gt;https://doi.org/10.1186/s13075-019-1981-0</mixed-citation></ref></ref-list></back></article>